zonisamide has been researched along with Abdominal Epilepsy in 79 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| " For the focal epilepsy trial, the non-inferiority limit (lamotrigine vs." | 9.41 | Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. ( Appleton, R; Baker, G; Balabanova, S; Brown, R; Burnside, G; Hindley, D; Howell, S; Hughes, DA; Leach, JP; Maguire, M; Marson, AG; Mohanraj, R; Plumpton, CO; Sills, G; Smith, D; Smith, PE; Taylor, C; Tudur-Smith, C; Williamson, PR, 2021) |
| "Zonisamide is licensed in the EU and USA for the adjunctive treatment of partial-onset seizures in adults but there are few data about its use in children." | 9.14 | Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. ( Conry, JA; Pellock, JM; Shinnar, S, 2009) |
| "Zonisamide (ZNS) is a new generation antiepileptic drug (AED) used in refractory epilepsy." | 8.12 | Effectiveness of zonisamide in childhood refractory epilepsy. ( Aslan, M; Gungor, S, 2022) |
| "The median percent reduction in weekly seizure frequency over the treatment period was 59." | 6.77 | Short-term efficacy and safety of zonisamide as adjunctive treatment for refractory partial seizures: a multicenter open-label single-arm trial in Korean patients. ( Cho, YW; Heo, K; Kim, KS; Kim, OJ; Kim, SE; Kim, SH; Lee, BI; Lee, JH; Lee, SJ; Park, SP; Shin, DJ; Song, HK; Yi, SD, 2012) |
| "Niño de 11 años con complejo esclerosis tuberosa y epilepsia refractaria del lobulo frontal izquierdo, evaluado en el contexto de un programa de cirugia de la epilepsia pediatrica." | 5.42 | [Reversible neuropsychological deterioration associated to zonisamide in a paediatric patient with tuberous sclerosis]. ( Blanco-Beregana, M; Budke, M; Fournier-Del Castillo, MC; Garcia-Fernandez, M; Garcia-Penas, JJ; Melero-Llorente, J; Perez-Jimenez, MÁ; Robles-Bermejo, F, 2015) |
| " For the focal epilepsy trial, the non-inferiority limit (lamotrigine vs." | 5.41 | Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. ( Appleton, R; Baker, G; Balabanova, S; Brown, R; Burnside, G; Hindley, D; Howell, S; Hughes, DA; Leach, JP; Maguire, M; Marson, AG; Mohanraj, R; Plumpton, CO; Sills, G; Smith, D; Smith, PE; Taylor, C; Tudur-Smith, C; Williamson, PR, 2021) |
| "Zonisamide has been associated with weight loss in children and adults." | 5.20 | Effects of adjunctive zonisamide treatment on weight and body mass index in children with partial epilepsy. ( Giorgi, L; Lagae, L; Meshram, C; Patten, A, 2015) |
| "Zonisamide is licensed in the EU and USA for the adjunctive treatment of partial-onset seizures in adults but there are few data about its use in children." | 5.14 | Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. ( Conry, JA; Pellock, JM; Shinnar, S, 2009) |
| "This literature review is devoted to the use of the antiepileptic drug zonisamide in the initial monotherapy of symptomatic and cryptogenic partial epilepsy." | 4.91 | [New possibilities of monotherapy of symptomatic and cryptogenic partial epilepsy]. ( Belova, YA; Rudakova, IG, 2015) |
| "Zonisamide is currently licensed in Europe and the USA for the adjunctive treatment of partial seizures (with or without secondary generalization) in adults, based on the results of four pivotal, randomized, double-blind, placebo-controlled trials." | 4.88 | Zonisamide in clinical practice. ( Dupont, S; Stefan, H, 2012) |
| "Zonisamide (ZNS) is a new generation antiepileptic drug (AED) used in refractory epilepsy." | 4.12 | Effectiveness of zonisamide in childhood refractory epilepsy. ( Aslan, M; Gungor, S, 2022) |
| "Zonisamide (Zonegran) has been used extensively worldwide (>2 million patient-years experience) for the effective treatment of a broad range of epilepsy indications." | 3.82 | Zonisamide as adjunctive therapy for refractory partial seizures. ( Brodie, MJ, 2006) |
| " The guidelines for clinical evaluation of antiepileptic drugs (AEDs), proposed by the International League Against Epilepsy in 1989, were scrutinized through our clinical experiences with zonisamide." | 3.68 | Methodological requirements for clinical trials in refractory epilepsies--our experience with zonisamide. ( Seino, M; Yagi, K, 1992) |
| "Lamotrigine was superior in the cost-utility analysis, with a higher net health benefit of 1·403 QALYs (97·5% central range 1·319-1·458) compared with 1·222 (1·110-1·283) for levetiracetam and 1·232 (1·112, 1·307) for zonisamide at a cost-effectiveness threshold of £20 000 per QALY." | 3.01 | The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. ( Appleton, R; Baker, GA; Balabanova, S; Brown, R; Burnside, G; Hindley, D; Howell, S; Hughes, DA; Leach, JP; Maguire, M; Marson, A; Mohanraj, R; Plumpton, C; Sills, G; Smith, D; Smith, PE; Taylor, C; Tudur-Smith, C; Williamson, P, 2021) |
| " The open phase did not reveal new adverse effects." | 2.80 | [Zonisamid in additional treatment of pediatric partial epilepsy: a review of efficacy and safety in randomized double blind pacebo-controlled III phase study]. ( Belousova, E, 2015) |
| " During the subsequent open-label period (45-57 weeks), zonisamide dosing could be adjusted according to tolerability/response." | 2.79 | Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: results of an open-label extension study of a phase III, randomized, double-blind, placebo-controlled trial. ( Bradshaw, K; Giorgi, L; Guerrini, R; Rosati, A, 2014) |
| "Zonisamide was associated with small-to-moderate decreases in bicarbonate levels from baseline (mean -3." | 2.79 | Long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: results of a phase III, randomized, double-blind study. ( Baulac, M; Giorgi, L; Patten, A, 2014) |
| "Zonisamide was initiated at 1 mg/kg/day, titrated to a target dose of 8 mg/kg/day over 8 weeks (one down-titration permitted), and maintained for 12 weeks." | 2.78 | A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. ( Bradshaw, K; Giorgi, L; Guerrini, R; Pellacani, S; Rosati, A; Segieth, J, 2013) |
| "Zonisamide was non-inferior to controlled-release carbamazepine--according to International League Against Epilepsy guidelines--and could be useful as an initial monotherapy for patients newly diagnosed with partial epilepsy." | 2.77 | Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. ( Baulac, M; Brodie, MJ; Giorgi, L; Patten, A; Segieth, J, 2012) |
| "The median percent reduction in weekly seizure frequency over the treatment period was 59." | 2.77 | Short-term efficacy and safety of zonisamide as adjunctive treatment for refractory partial seizures: a multicenter open-label single-arm trial in Korean patients. ( Cho, YW; Heo, K; Kim, KS; Kim, OJ; Kim, SE; Kim, SH; Lee, BI; Lee, JH; Lee, SJ; Park, SP; Shin, DJ; Song, HK; Yi, SD, 2012) |
| " There was no difference in the incidence of adverse effects between zonisamide and placebo." | 2.76 | Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebo-controlled trial. ( Chen, Y; Hu, Y; Lu, Y; Wang, X; Xiao, F; Xiao, Z; Yu, W, 2011) |
| "To assess the efficacy and tolerability of zonisamide in a study allowing flexible dosing in a more diverse and less refractory population than assessed in randomized controlled trials." | 2.75 | Flexible dosing of adjunctive zonisamide in the treatment of adult partial-onset seizures: a non-comparative, open-label study (ZEUS). ( Baker, G; Dupont, S; Ellis, S; Giallonardo, AT; Smith, P; Springub, J; Striano, S; Trinka, E; Yeates, A, 2010) |
| "Patients with refractory partial epilepsy who completed a fixed-dose, randomized, double-blind clinical trial were recruited in an open-label extension study with adjustment of zonisamide and other antiepileptic drug dosage according to the treating physician's usual clinical practice." | 2.73 | Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy. ( Marshall, A; Wroe, SJ; Yeates, AB, 2008) |
| " For all seizures, a significant dose-response relation was observed (p < 0." | 2.71 | Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. ( Bitenskyy, V; Brodie, MJ; Duncan, R; Lucas, C; Solyom, A; Vespignani, H, 2005) |
| " The minimal effective dosage was 100 mg/d, but 400 mg/d was the most effective dosage." | 2.70 | Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. ( Ayala, R; Faught, E; Leppik, IE; Montouris, GG, 2001) |
| "Zonisamide is an effective antiepileptic drug for add-on treatment of refractory partial epilepsy." | 2.67 | Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. ( Bauer, G; Blankenhorn, V; Deisenhammer, E; Despland, A; Egli, M; Jacob, R; Klinger, D; Loiseau, P; Schmidt, D; Stenzel, E, 1993) |
| " Two trials provided evidence of a dose-response relationship for this outcome." | 2.66 | Zonisamide add-on therapy for focal epilepsy. ( Behzadifar, M; Bragazzi, NL; Brigo, F; Igwe, SC; Lattanzi, S, 2020) |
| "It is also effective in generalized epilepsy and in several other conditions of the CNS." | 2.61 | An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy. ( Ljung, H; Reimers, A, 2019) |
| " Two trials provided evidence of a dose-response relationship for this outcome." | 2.58 | Zonisamide add-on therapy for focal epilepsy. ( Behzadifar, M; Bragazzi, NL; Brigo, F; Igwe, SC; Lattanzi, S, 2018) |
| "Epilepsy is a common neurological condition with a worldwide prevalence of around 1%." | 2.55 | Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. ( Marson, AG; Nevitt, SJ; Sudell, M; Tudur Smith, C; Weston, J, 2017) |
| "Epilepsy is a common neurological condition with a worldwide prevalence of around 1%." | 2.55 | Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. ( Marson, AG; Nevitt, SJ; Sudell, M; Tudur Smith, C; Weston, J, 2017) |
| " Adverse effects include somnolence and weight decrease, but data suggest that long-term treatment with ZNS is safe with only rare newly occurring adverse effects, and good long-term tolerability also regarding mood, behavior, cognition and bone maturation." | 2.52 | The safety and long-term efficacy of zonisamide as adjunctive therapy for focal epilepsy. ( Schulze-Bonhage, A, 2015) |
| "Zonisamide was generally well tolerated in these studies, with the majority of adverse events being mild or moderate in severity." | 2.50 | Zonisamide: a review of its use as adjunctive therapy in the management of partial seizures in pediatric patients aged ≥6 years. ( Hoy, SM, 2014) |
| "Zonisamide has efficacy as an add-on treatment in people with drug-resistant partial epilepsy." | 2.49 | Zonisamide add-on for drug-resistant partial epilepsy. ( Carmichael, K; Lakhan, SE; Marson, AG; Parikh, P; Pulman, J, 2013) |
| "Zonisamide was generally well tolerated in adults with partial seizures participating in these studies, with the majority of adverse events being mild or moderate in severity." | 2.49 | Zonisamide: a review of its use in the management of adults with partial seizures. ( Hoy, SM, 2013) |
| " Once-daily dosing is indicated, considering the long plasma half-life and linear pharmacokinetics of the drug." | 2.49 | Profile of once-daily zonisamide as monotherapy for treatment of partial seizures in adults. ( Mula, M, 2013) |
| "Zonisamide has no clinically relevant effects on the pharmacokinetics of other commonly used AEDs, however, co-administration with cytochrome P450 3A4 (CYP3A4) inducers or inhibitors may change zonisamide's pharmacokinetic profile." | 2.44 | Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. ( Baulac, M; Leppik, IE, 2007) |
| "Zonisamide has efficacy as an add-on treatment in people with drug-resistant partial epilepsy." | 2.43 | Zonisamide add-on for drug-resistant partial epilepsy. ( Chadwick, DW; Marson, AG, 2005) |
| "Zonisamide has a long T1/2 enabling once-daily dosing, linear pharmacokinetics and minimal interaction with other drugs; plasma levels of commonly administered AEDs and oral contraceptives are unaffected by concomitant zonisamide." | 2.43 | Introduction to zonisamide. ( Baulac, M, 2006) |
| "Zonisamide is an antiepilepsy drug (AED) with both sodium and calcium channel-blocking properties." | 2.42 | Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. ( Faught, E, 2004) |
| "Zonisamide has efficacy as an add-on treatment in patients with drug-resistant partial epilepsy." | 2.41 | Zonisamide for drug-resistant partial epilepsy. ( Chadwick, DW; Marson, AG, 2000) |
| "Levetiracetam has the more favourable 'responder-withdrawal ratio' followed by zonisamide and oxcarbazepine." | 2.41 | Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. ( Castillo, S; Chadwick, DW; Chaisewikul, R; Hutton, JL; Leach, JP; Marson, AG; Privitera, M; Schmidt, D; White, S, 2001) |
| "Zonisamide has efficacy as an add-on treatment in people with drug-resistant partial epilepsy." | 2.41 | Zonisamide add-on for drug-resistant partial epilepsy. ( Chadwick, DW; Marson, AG, 2002) |
| "The model predicts disease progression and seizures, relevant and most common adverse events, withdrawal due to lack of efficacy or adverse events, and epilepsy-specific and all-cause mortality over a 2-year time horizon." | 1.51 | Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system. ( Charokopou, M; Christou, P; Geitona, M; Giannakodimos, S; Kimiskidis, VK; Kountouris, V; Stamuli, E, 2019) |
| "Median weight loss was 8kg (range: 2-16)." | 1.46 | Efficacy, tolerability, and retention rates of zonisamide in older adult patients with focal-onset epilepsy: Experiences from two tertiary epilepsy centers. ( Doğan, EA; Erdoğan, Ç; Genç, BO; Genç, E, 2017) |
| "Niño de 11 años con complejo esclerosis tuberosa y epilepsia refractaria del lobulo frontal izquierdo, evaluado en el contexto de un programa de cirugia de la epilepsia pediatrica." | 1.42 | [Reversible neuropsychological deterioration associated to zonisamide in a paediatric patient with tuberous sclerosis]. ( Blanco-Beregana, M; Budke, M; Fournier-Del Castillo, MC; Garcia-Fernandez, M; Garcia-Penas, JJ; Melero-Llorente, J; Perez-Jimenez, MÁ; Robles-Bermejo, F, 2015) |
| "Thirteen patients affected by focal epilepsy were recruited to undergo a 24-hour ambulatory polysomnography, Multiple Sleep Latency Test (MSLT), and a subjective evaluation of nocturnal sleep by means of the Pittsburgh Sleep Quality Index (PSQI) and daytime somnolence by means of the Epworth Sleepiness Scale (ESS) before and after 3 months of treatment with ZNS as add-on therapy." | 1.39 | Effects of zonisamide as add-on therapy on sleep-wake cycle in focal epilepsy: a polysomnographic study. ( Copetti, M; Cum, F; Del Bianco, C; Evangelista, E; Izzi, F; Marciani, MG; Mercuri, NB; Placidi, F; Romigi, A; Vitrani, G; Zannino, S, 2013) |
| " The most common reported adverse effects are somnolence, anorexia, dizziness, and headache." | 1.37 | Moderate toxic effects following acute zonisamide overdose. ( Ceschi, A; Hofer, KE; Kullak-Ublick, GA; Kupferschmidt, H; Rauber-Lüthy, C; Trachsel, C, 2011) |
| "The ZNS daily dosage varied between 100 mg and 500 mg (mean 368 mg)." | 1.35 | [Zonisamide as add-on treatment for focal epilepsies. An outcome analysis of 74 patients]. ( Bauer, J; Wellmer, J; Wellmer, S, 2008) |
| " Seizure count and side effect profile were maintained during therapy." | 1.33 | Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. ( Hobdell, E; Kaleyias, J; Khurana, DS; Kothare, SV; Legido, A; Melvin, JJ; Mostofi, N; Valencia, I, 2006) |
| "Zonisamide is an adjuvant for the treatment of patients with partial epilepsy, with or without secondary generalisation." | 1.33 | [New medications; zonisamide]. ( Cohen, AF; van Bronswijk, H, 2006) |
| "Zonisamide was administered at age 6 years, which was effective against her seizures, but selective mutism, violent behaviour, and lack of concentration developed at age 10 years." | 1.31 | Selective mutism and obsessive compulsive disorders associated with zonisamide. ( Hirai, K; Jozaki, K; Kimiya, S; Kumagai, N; Seki, T; Tabata, K, 2002) |
| "Distal renal tubular acidosis was diagnosed." | 1.31 | Renal tubular acidosis associated with zonisamide therapy. ( Gondo, K; Hara, T; Ikeda, K; Inoue, T; Kaku, Y; Kira, R, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.27) | 18.7374 |
| 1990's | 6 (7.59) | 18.2507 |
| 2000's | 33 (41.77) | 29.6817 |
| 2010's | 34 (43.04) | 24.3611 |
| 2020's | 5 (6.33) | 2.80 |
| Authors | Studies |
|---|---|
| Marson, AG | 8 |
| Burnside, G | 2 |
| Appleton, R | 2 |
| Smith, D | 2 |
| Leach, JP | 3 |
| Sills, G | 2 |
| Tudur-Smith, C | 2 |
| Plumpton, CO | 1 |
| Hughes, DA | 2 |
| Williamson, PR | 1 |
| Baker, G | 2 |
| Balabanova, S | 2 |
| Taylor, C | 2 |
| Brown, R | 2 |
| Hindley, D | 2 |
| Howell, S | 2 |
| Maguire, M | 2 |
| Mohanraj, R | 2 |
| Smith, PE | 2 |
| Aslan, M | 1 |
| Gungor, S | 1 |
| Janković, SM | 1 |
| Brigo, F | 2 |
| Lattanzi, S | 2 |
| Igwe, SC | 2 |
| Behzadifar, M | 2 |
| Bragazzi, NL | 2 |
| Marson, A | 1 |
| Plumpton, C | 1 |
| Williamson, P | 1 |
| Baker, GA | 1 |
| Nevitt, SJ | 2 |
| Sudell, M | 2 |
| Weston, J | 2 |
| Tudur Smith, C | 2 |
| Doğan, EA | 1 |
| Genç, E | 1 |
| Genç, BO | 1 |
| Erdoğan, Ç | 1 |
| Rosdy, B | 1 |
| Kollár, K | 1 |
| Móser, J | 1 |
| Mellár, M | 1 |
| Geitona, M | 1 |
| Stamuli, E | 1 |
| Giannakodimos, S | 1 |
| Kimiskidis, VK | 1 |
| Kountouris, V | 1 |
| Charokopou, M | 1 |
| Christou, P | 1 |
| Reimers, A | 1 |
| Ljung, H | 1 |
| Imataka, G | 1 |
| Noguchi, M | 1 |
| Tsukada, K | 1 |
| Takahashi, T | 1 |
| Yamanouchi, H | 1 |
| Arisaka, O | 1 |
| Rubio-Nazabal, E | 1 |
| Alvarez-Pérez, P | 1 |
| Lema-Facal, T | 1 |
| López-Facal, S | 1 |
| Mula, M | 1 |
| Guerrini, R | 2 |
| Rosati, A | 2 |
| Segieth, J | 2 |
| Pellacani, S | 1 |
| Bradshaw, K | 2 |
| Giorgi, L | 5 |
| Hoy, SM | 2 |
| Carmichael, K | 1 |
| Pulman, J | 1 |
| Lakhan, SE | 1 |
| Parikh, P | 1 |
| Cox, JH | 1 |
| Seri, S | 1 |
| Cavanna, AE | 1 |
| Baulac, M | 4 |
| Patten, A | 3 |
| Fournier-Del Castillo, MC | 1 |
| Melero-Llorente, J | 1 |
| Blanco-Beregana, M | 1 |
| Robles-Bermejo, F | 1 |
| Budke, M | 1 |
| Garcia-Fernandez, M | 1 |
| Garcia-Penas, JJ | 1 |
| Perez-Jimenez, MÁ | 1 |
| Lagae, L | 1 |
| Meshram, C | 1 |
| Schulze-Bonhage, A | 1 |
| Janszky, J | 1 |
| Horvath, R | 1 |
| Komoly, S | 1 |
| Belousova, E | 1 |
| Rudakova, IG | 1 |
| Belova, YA | 1 |
| Mintzer, S | 1 |
| Miller, R | 1 |
| Shah, K | 1 |
| Chervoneva, I | 1 |
| Nei, M | 1 |
| Skidmore, C | 1 |
| Sperling, MR | 1 |
| Wandschneider, B | 1 |
| Burdett, J | 1 |
| Townsend, L | 1 |
| Hill, A | 1 |
| Thompson, PJ | 1 |
| Duncan, JS | 1 |
| Koepp, MJ | 1 |
| Wroe, SJ | 1 |
| Yeates, AB | 1 |
| Marshall, A | 1 |
| Zachry, WM | 1 |
| Doan, QD | 1 |
| Clewell, JD | 1 |
| Smith, BJ | 1 |
| Wellmer, S | 1 |
| Wellmer, J | 1 |
| Bauer, J | 1 |
| Rouvel-Tallec, A | 1 |
| Dupont, S | 2 |
| Striano, S | 1 |
| Trinka, E | 1 |
| Springub, J | 1 |
| Giallonardo, AT | 1 |
| Smith, P | 1 |
| Ellis, S | 1 |
| Yeates, A | 1 |
| Lu, Y | 1 |
| Xiao, Z | 2 |
| Yu, W | 1 |
| Xiao, F | 1 |
| Hu, Y | 1 |
| Chen, Y | 1 |
| Wang, X | 1 |
| Hofer, KE | 1 |
| Trachsel, C | 1 |
| Rauber-Lüthy, C | 1 |
| Kupferschmidt, H | 1 |
| Kullak-Ublick, GA | 1 |
| Ceschi, A | 1 |
| Helmstaedter, C | 1 |
| Stefan, H | 2 |
| Witt, JA | 1 |
| Heo, K | 1 |
| Lee, BI | 1 |
| Yi, SD | 1 |
| Cho, YW | 1 |
| Shin, DJ | 1 |
| Song, HK | 2 |
| Kim, OJ | 1 |
| Park, SP | 1 |
| Kim, SE | 1 |
| Kim, SH | 1 |
| Lee, JH | 1 |
| Kim, KS | 1 |
| Lee, SJ | 1 |
| Abou-Khalil, BW | 1 |
| Brodie, MJ | 3 |
| Romigi, A | 1 |
| Izzi, F | 1 |
| Placidi, F | 1 |
| Zannino, S | 1 |
| Evangelista, E | 1 |
| Del Bianco, C | 1 |
| Copetti, M | 1 |
| Vitrani, G | 1 |
| Mercuri, NB | 1 |
| Cum, F | 1 |
| Marciani, MG | 1 |
| van Rijckevorsel, K | 1 |
| Boon, PA | 1 |
| Hirai, K | 1 |
| Kimiya, S | 1 |
| Tabata, K | 1 |
| Seki, T | 1 |
| Jozaki, K | 1 |
| Kumagai, N | 1 |
| French, JA | 3 |
| Kanner, AM | 3 |
| Bautista, J | 3 |
| Abou-Khalil, B | 3 |
| Browne, T | 3 |
| Harden, CL | 3 |
| Theodore, WH | 3 |
| Bazil, C | 3 |
| Stern, J | 3 |
| Schachter, SC | 3 |
| Bergen, D | 3 |
| Hirtz, D | 3 |
| Montouris, GD | 3 |
| Nespeca, M | 3 |
| Gidal, B | 3 |
| Marks, WJ | 3 |
| Turk, WR | 3 |
| Fischer, JH | 3 |
| Bourgeois, B | 3 |
| Wilner, A | 3 |
| Faught, RE | 3 |
| Sachdeo, RC | 3 |
| Beydoun, A | 3 |
| Glauser, TA | 3 |
| Sackellares, JC | 1 |
| Ramsay, RE | 1 |
| Wilder, BJ | 1 |
| Browne, TR | 1 |
| Shellenberger, MK | 1 |
| Faught, E | 2 |
| Duncan, R | 1 |
| Vespignani, H | 1 |
| Solyom, A | 1 |
| Bitenskyy, V | 1 |
| Lucas, C | 1 |
| Frampton, JE | 1 |
| Scott, LJ | 1 |
| Mandelbaum, DE | 2 |
| Bunch, M | 2 |
| Kugler, SL | 2 |
| Venkatasubramanian, A | 2 |
| Wollack, JB | 2 |
| Chadwick, DW | 4 |
| Kothare, SV | 1 |
| Kaleyias, J | 1 |
| Mostofi, N | 1 |
| Valencia, I | 1 |
| Melvin, JJ | 1 |
| Hobdell, E | 1 |
| Khurana, DS | 1 |
| Legido, A | 1 |
| Cohen, AF | 1 |
| van Bronswijk, H | 1 |
| Leppik, IE | 2 |
| Macleod, S | 1 |
| Appleton, RE | 1 |
| Shinnar, S | 1 |
| Pellock, JM | 1 |
| Conry, JA | 1 |
| Tsuji, M | 1 |
| Hori, S | 1 |
| Asai, N | 1 |
| Hamanaka, T | 1 |
| Ishikawa, T | 1 |
| Hiyoshi, T | 1 |
| Mochizuki, H | 1 |
| Schmidt, D | 2 |
| Jacob, R | 1 |
| Loiseau, P | 1 |
| Deisenhammer, E | 1 |
| Klinger, D | 1 |
| Despland, A | 1 |
| Egli, M | 1 |
| Bauer, G | 1 |
| Stenzel, E | 1 |
| Blankenhorn, V | 1 |
| Ikeda, A | 1 |
| Hattori, H | 1 |
| Odani, A | 1 |
| Kimura, J | 1 |
| Shibasaki, H | 1 |
| White, HS | 1 |
| Inoue, T | 1 |
| Kira, R | 1 |
| Kaku, Y | 1 |
| Ikeda, K | 1 |
| Gondo, K | 1 |
| Hara, T | 1 |
| Miura, H | 1 |
| Hutton, JL | 1 |
| Castillo, S | 1 |
| White, S | 1 |
| Chaisewikul, R | 1 |
| Privitera, M | 1 |
| Ayala, R | 1 |
| Montouris, GG | 1 |
| Hamada, K | 1 |
| Ishida, S | 1 |
| Yagi, K | 3 |
| Seino, M | 3 |
| Haruda, FD | 1 |
| Fujikawa, Y | 1 |
| Kubota, H | 1 |
| Matsuda, K | 1 |
| Fujiwara, T | 1 |
| Shimizu, A | 1 |
| Yamamoto, J | 1 |
| Yamada, Y | 1 |
| Tanaka, M | 1 |
| Kawasaki, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Characterization of Epilepsy Patients At-risk for Adverse Outcomes Related to Switching Antiepileptic Drug Products: BEEP 2b Study[NCT02707965] | Phase 1 | 21 participants (Actual) | Interventional | 2017-06-08 | Completed | ||
| A Randomized Controlled Trial of Generic Substitution of Antiepileptic Drugs[NCT02429596] | Phase 4 | 200 participants (Anticipated) | Interventional | 2012-05-31 | Recruiting | ||
| A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy[NCT00477295] | Phase 3 | 583 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Phase 3: Metabolism of Lamotrigine During Treatment With Oral Contraceptives[NCT00266149] | Phase 3 | 10 participants | Interventional | 2003-06-30 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
summed for each anti-epileptic drug from when taking brand and generic. (NCT02707965)
Timeframe: Through the approximately 2 week period when the treatment is given.
| Intervention | events (Number) |
|---|---|
| Topiramate | 29 |
| Lamotrigine ER | 9 |
| Levetiracetam IR | 17 |
| Levetiracetam ER | 4 |
| Carbamazepine ER Capsule | 15 |
| Zonisamide | 6 |
| Carbamazepine ER Tablet | 10 |
| Valproic Acid | 10 |
Average AUC (area under the drug plasma curve. (NCT02707965)
Timeframe: For all study drugs, time points are: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 hr postdose. For twice-a-day regimen, additional points are:8, 10, and 12 hr postdose. For once-a-day drugs, additional times are:8, 10, 12, 16, and 24 hr postdose.
| Intervention | micro/mL/hr (Mean) | |
|---|---|---|
| Test Product | Reference Product | |
| Carbamazepine ER Capsule | 114.96 | 106.45 |
| Carbamazepine ER Tablet | 104.6 | 115.16 |
| Lamotrigine ER Tablet | 62.76666667 | 67.19333333 |
| Levetiracetam ER Tablet | 260.3 | 262.305 |
| Levetiracetam IR Tablet | 419.97 | 445.2 |
| Topiramate Tablet | 92.884 | 94.456 |
| Zonisamide Capsule | 233.16 | 226.14 |
Average maximum drug plasma concentration; (NCT02707965)
Timeframe: For all study drugs, time points are: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 hr postdose. For twice-a-day regimen, additional points are:8, 10, and 12 hr postdose. For once-a-day drugs, additional times are:8, 10, 12, 16, and 24 hr postdose.
| Intervention | microg/mL (Mean) | |
|---|---|---|
| Test Product | Reference Product | |
| Carbamazepine ER Capsule | 10.95 | 9.91 |
| Carbamazepine ER Tablet | 10.00 | 10.6 |
| Lamotrigine ER Tablet | 6.24 | 6.903333333 |
| Levetiracetam ER Tablet | 31.05 | 28.04 |
| Levetiracetam IR Tablet | 71.02333333 | 69.29333333 |
| Topiramate Tablet | 9.874 | 9.646 |
| Zonisamide Capsule | 12.29 | 11.68 |
Average minimum drug plasma concentration (Cmin); (NCT02707965)
Timeframe: For all study drugs, time points are: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 hr postdose. For twice-a-day regimen, additional points are:8, 10, and 12 hr postdose. For once-a-day drugs, additional times are:8, 10, 12, 16, and 24 hr postdose.
| Intervention | microg/mL (Mean) | |
|---|---|---|
| Test Product | Reference Product | |
| Carbamazepine ER Capsule | 8.56 | 7.66 |
| Carbamazepine ER Tablet | 7.37 | 7.97 |
| Lamotrigine ER Tablet | 4.053333333 | 4.21 |
| Levetiracetam ER Tablet | 12.605 | 14.395 |
| Levetiracetam IR Tablet | 15.45333333 | 17.45666667 |
| Topiramate Tablet | 6.326 | 6.53 |
| Zonisamide Capsule | 8.46 | 8.34 |
Number of seizures reported in all groups (NCT02707965)
Timeframe: Through the approximately 2 week period when the treatment is given.
| Intervention | Number of Seizures (Number) | |
|---|---|---|
| Reference Product | Test (Generic) | |
| Carbamazepine ER Capsule | 3 | 1 |
| Carbamazepine ER Tablet | 0 | 0 |
| Lamotrigine ER Tablet Group | 44 | 25 |
| Lamotrigine IR Tablet Group | 0 | 0 |
| Levetiracetam ER Tablet Group | 42 | 72 |
| Levetiracetam IR Tablet Group | 16 | 5 |
| Topiramate Tablet Group | 9 | 5 |
| Valproic Acid ER Tablet Group | 12 | 0 |
| Zonisamide Capsule Group | 0 | 0 |
An AE is defined as any untoward medical occurrence in a subject and does not necessarily have a causal relationship with the medicinal product. Adverse events were identified by: any unfavorable or unintended sign, symptom or disease temporarily associated with the use of a medicinal product; any new disease or exacerbation of an existing disease; any deterioration in nonprotocol-required measurements of laboratory values or other clinical test; and recurrence of an intermittent medical condition not present at Baseline. (NCT00477295)
Timeframe: Week 1 through Week 109
| Intervention | Median Days (Median) |
|---|---|
| Zonisamide | NA |
| Carbamazepine | NA |
Lack of efficacy was evaluated by the subject and on the basis of whether zonisamide and carbamazepine gave the subject at least a 26-week seizure free rate. The subject could withdraw at any time due to lack of efficacy. (NCT00477295)
Timeframe: Week 1 through Week 109
| Intervention | Median Days (Median) |
|---|---|
| Zonisamide | 722 |
| Carbamazepine | NA |
"The Quality of Life in Epilepsy - Problems(QOLIE-31-P) was completed by the patient and contained 30 items covering seven subscales(seizure worry, overall~Quality of Life (QOL),emotional well-being,energy-fatigue, cognition,medication effects and social function) and one item covering health status. It also included seven items addressing overall distress related to each subscale, an item addressing the relative importance of each subscale topic, and an item addressing perception of overall change in QOL at the end of the study. A high score reflects a good QOL. The following scale range is a sample of 1 of the 7 of the subscales:~10 (Best possible quality of life) - 0 (Worst possible quality of life);~Rand Corporation QOLIE-31 Scoring Manual was used. The QOLIE-31 overall score is calculated by summing the product of each scale score times its weight and summing overall all scales." (NCT00477295)
Timeframe: Baseline and Maintenance Period Visit 1 (Week 31 to Week 83)
| Intervention | Scores on a Scale (Mean) |
|---|---|
| Zonisamide | 4.474 |
| Carbamazepine | 6.090 |
The Aldenkamp-Baker Neuropsychological Assessment Scale(ABNAS) is a subject based questionnaire to measure subjective perceived drug-related cognitive impairments. The ABNAS measured seven critical domains of cognition(tiredness/fatigue,hyperexcitability, slowing(mental and motor),memory impairment,attention disorders,impairment of motor coordination, and language disorders). The total score ranged from 0 to 72, with a higher score reflecting a high level of problems. (NCT00477295)
Timeframe: Baseline and Maintenance Period Visit 1 (Week 31 to Week 83)
| Intervention | Scores on a Scale (Mean) |
|---|---|
| Zonisamide | 1.6 |
| Carbamazepine | -0.1 |
A subject achieved a 12-month seizure-free period if they were free of all seizures, regardless of seizure type, for 12 months while receiving the same dose. The occurrence of seizures was documented in the seizure diary, which was maintained by the subject and reviewed at each following visit. (NCT00477295)
Timeframe: Week 5 through Week 109
| Intervention | Percentage of participants (Number) |
|---|---|
| Zonisamide | 67.6 |
| Carbamazepine | 74.7 |
A subject achieved a 26-week seizure-free period if they were free of all seizures, regardless of seizure type, for 26 weeks while receiving the same dose. The occurrence of seizures was documented in the seizure diary, which was maintained by the subject and reviewed at each following visit. (NCT00477295)
Timeframe: Week 31 through Week 109
| Intervention | Percentage of Participants (Number) |
|---|---|
| Zonisamide | 79.4 |
| Carbamazepine | 83.7 |
A subject achieved a 12-month seizure-free period if they were free of all seizures, regardless of seizure type, for 12-months while receiving the same dose. The occurrence of seizures was documented in the seizure diary, which was maintained by the subject and reviewed at each following visit. (NCT00477295)
Timeframe: Week 5 through Week 83
| Intervention | Days (Mean) |
|---|---|
| Zonisamide | 399.3 |
| Carbamazepine | 395.6 |
A subject achieved a 6-months seizure-free period if they were free of all seizures, regardless of seizure type, for 6-months while receiving the same dose. The occurrence of seizures was documented in the seizure diary, which was maintained by the subject and reviewed at each following visit. (NCT00477295)
Timeframe: Week 5 through Week 83
| Intervention | Days (Mean) |
|---|---|
| Zonisamide | 222.7 |
| Carbamazepine | 220.4 |
"The Bond-Lader Visual Analogue Scale (VAS) is made up of 16 pairs of alternative descriptors of mood and attention at either end of a 10 cm line.~Subjects were asked to rate their feelings at the time of assessment by indicating the point on the line which best represent their mood. Each item was scored by measuring the position relative to the left hand end of the line and levels of anxiety, sedation, and dysphoria were then calculated from the combined scores of selected items. The scores ranged from 0 to 100, with a high score reflecting a high level of anxiety, sedation or dysphoria." (NCT00477295)
Timeframe: Baseline and Maintenance Period Visit 1 (Week 31 to Week 83)
| Intervention | Scores on a Scale (Mean) | ||
|---|---|---|---|
| Anxiety | Sedation | Dysphoria | |
| Carbamazepine | -1.993 | -1.362 | -3.833 |
| Zonisamide | -2.036 | -0.475 | -1.930 |
The Short Form 36 Health and Well-Being Questionnaire (SF-36) is a 36-item generic health related QOL instrument covering the following domains: physical functioning, role-physical,bodily pain, general health, social functioning,role-emotional, mental health, and vitality. It yields a profile of eight scores, one for each domain, and physical and mental health summary measures. Each domain is described by a score ranging from 0 to 100, for a range of total possible scoes of 0-400 for physical and 0-400 for mental. An increase represents an improvement, whereas a decrease reflects a worsening. (NCT00477295)
Timeframe: Baseline and Maintenance Period Visit 1 (Week 31 to Week 83)
| Intervention | Scores on a Scale (Mean) | |
|---|---|---|
| Aggregate Mental Component Score | Aggregate Physical Component Score | |
| Carbamazepine | 2.495 | 2.041 |
| Zonisamide | 1.027 | 1.895 |
The European Quality of Life Group 5-Dimension Self-Report Questionnaire (EQ-5D) is a preference based generic health related quality of life (HRQoL) instrument which classifies health states across five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain has three levels, they are (1) no problems, (2) some problems, (3) extreme problems. The percentages shown are calculated from the number of subjects at that visit with non-missing data for that score. (NCT00477295)
Timeframe: Week 31 through Week 83
| Intervention | Percentage of Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mobility: No problems | Mobility: Some problems | Mobility: Confined to Bed | Self-Care:No problems | Self-Care: Some problems | Self-Care: Unable to wash or dress | Usual Activities: No problems | Usual Activities: Some problems | Usual Activities: Unable to perform | Pain/Discomfort: None | Pain/Discomfort: Moderate | Pain/Discomfort: Extreme | Anxiety/Depression: None | Anxiety/Depression: Moderate | Anxiety/Depression: Extreme | |
| Carbamazepine | 86.7 | 12.9 | 0.5 | 97.6 | 2.4 | 0.0 | 84.8 | 15.2 | 0.0 | 73.2 | 25.4 | 1.4 | 62.9 | 34.8 | 2.4 |
| Zonisamide | 90.8 | 8.7 | 0.5 | 96.7 | 2.7 | 0.5 | 89.1 | 9.8 | 1.1 | 75.5 | 22.3 | 2.2 | 64.3 | 31.3 | 4.4 |
30 reviews available for zonisamide and Abdominal Epilepsy
| Article | Year |
|---|---|
Evaluation of zonisamide for the treatment of focal epilepsy: a review of pharmacokinetics, clinical efficacy and adverse effects.
Topics: Anticonvulsants; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Epilepsi | 2020 |
Zonisamide add-on therapy for focal epilepsy.
Topics: Anticonvulsants; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, Partial; Humans; In | 2020 |
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Epilepsies, Parti | 2017 |
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Epilepsies, Parti | 2017 |
[The role of zonisamide in the management of pediatric partial epilepsy].
Topics: Adolescent; Anticonvulsants; Child; Epilepsies, Partial; Female; Humans; Isoxazoles; Male; Zonisamid | 2016 |
Zonisamide add-on therapy for focal epilepsy.
Topics: Anticonvulsants; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, Partial; Humans; In | 2018 |
An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Epilepsies, Partial; Epilepsy, Generalized; Humans; Se | 2019 |
Profile of once-daily zonisamide as monotherapy for treatment of partial seizures in adults.
Topics: Anticonvulsants; Drug Administration Schedule; Epilepsies, Partial; Humans; Isoxazoles; Zonisamide | 2013 |
Zonisamide: a review of its use in the management of adults with partial seizures.
Topics: Adult; Aged; Anticonvulsants; Epilepsies, Partial; Humans; Isoxazoles; Middle Aged; Randomized Contr | 2013 |
Zonisamide add-on for drug-resistant partial epilepsy.
Topics: Anticonvulsants; Drug Resistance; Drug Therapy, Combination; Epilepsies, Partial; Humans; Isoxazoles | 2013 |
Zonisamide as a treatment for partial epileptic seizures: a systematic review.
Topics: Anticonvulsants; Epilepsies, Partial; Humans; Isoxazoles; Treatment Outcome; Zonisamide | 2014 |
Zonisamide: a review of its use as adjunctive therapy in the management of partial seizures in pediatric patients aged ≥6 years.
Topics: Anticonvulsants; Child; Drug Therapy, Combination; Epilepsies, Partial; Humans; Isoxazoles; Treatmen | 2014 |
The safety and long-term efficacy of zonisamide as adjunctive therapy for focal epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Cohort Studies; Combined Modality Therapy; | 2015 |
[ZONISAMIDE: FIRST CHOICE AMONG THE FIRST-LINE ANTIEPILEPTIC DRUGS IN FOCAL EPILEPSY].
Topics: Adolescent; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Drug Administratio | 2015 |
[New possibilities of monotherapy of symptomatic and cryptogenic partial epilepsy].
Topics: Anticonvulsants; Carbamazepine; Epilepsies, Partial; Epilepsy; Humans; Isoxazoles; Zonisamide | 2015 |
Zonisamide in clinical practice.
Topics: Anticonvulsants; Epilepsies, Partial; Humans; Isoxazoles; Quality of Life; Seizures; Treatment Outco | 2012 |
Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
Topics: Acetates; Adolescent; Adult; Age Factors; Amines; Antipsychotic Agents; Carbamazepine; Child; Clinic | 2004 |
Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
Topics: Acetates; Adolescent; Adult; Age Factors; Amines; Anticonvulsants; Carbamazepine; Child; Clinical Tr | 2004 |
Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epile
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Child; Clinical Trials as Topic; Cyclohexan | 2004 |
Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures.
Topics: Anticonvulsants; Clinical Trials as Topic; Epilepsies, Partial; Europe; Humans; Isoxazoles; Kidney C | 2004 |
Zonisamide: a review of its use in the management of partial seizures in epilepsy.
Topics: Anticonvulsants; Disease Management; Epilepsies, Partial; Humans; Isoxazoles; Zonisamide | 2005 |
Zonisamide add-on for drug-resistant partial epilepsy.
Topics: Anticonvulsants; Drug Resistance; Epilepsies, Partial; Humans; Isoxazoles; Randomized Controlled Tri | 2005 |
Zonisamide as adjunctive therapy for refractory partial seizures.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combinatio | 2006 |
Introduction to zonisamide.
Topics: Anticonvulsants; Clinical Trials as Topic; Drug Therapy, Combination; Epilepsies, Partial; Humans; I | 2006 |
Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures.
Topics: Animals; Anticonvulsants; Child; Dose-Response Relationship, Drug; Drug Resistance; Epilepsies, Part | 2007 |
The new antiepileptic drugs.
Topics: Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Dioxolanes; Epilepsies, | 2007 |
Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Epilepsies, Partial; Felbamate; Fru | 1999 |
Zonisamide for drug-resistant partial epilepsy.
Topics: Anticonvulsants; Epilepsies, Partial; Humans; Isoxazoles; Treatment Failure; Zonisamide | 2000 |
Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review.
Topics: Acetamides; Anticonvulsants; Carbamazepine; Controlled Clinical Trials as Topic; Drug Resistance; Ep | 2001 |
Zonisamide add-on for drug-resistant partial epilepsy.
Topics: Anticonvulsants; Epilepsies, Partial; Humans; Isoxazoles; Randomized Controlled Trials as Topic; Tre | 2002 |
20 trials available for zonisamide and Abdominal Epilepsy
| Article | Year |
|---|---|
Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
Topics: Child, Preschool; Cost-Benefit Analysis; Epilepsies, Partial; Epilepsy; Female; Humans; Lamotrigine; | 2021 |
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticonvulsants; Child; Cost-Benefit Analysis; Epilep | 2021 |
A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Double-Blind Method; Drug Therapy, Combination; Epilepsies, Part | 2013 |
Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: results of an open-label extension study of a phase III, randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Anticonvulsants; Child; Double-Blind Method; Epilepsies, Partial; Female; Humans; Isoxaz | 2014 |
Long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: results of a phase III, randomized, double-blind study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Delayed-Action Preparations; Double-Blind M | 2014 |
Effects of adjunctive zonisamide treatment on weight and body mass index in children with partial epilepsy.
Topics: Adolescent; Anticonvulsants; Body Mass Index; Child; Epilepsies, Partial; Female; Humans; Isoxazoles | 2015 |
[Zonisamid in additional treatment of pediatric partial epilepsy: a review of efficacy and safety in randomized double blind pacebo-controlled III phase study].
Topics: Adolescent; Anticonvulsants; Child; Double-Blind Method; Epilepsies, Partial; Female; Humans; Isoxaz | 2015 |
Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Resistance; Epilepsies, Partial; Humans; Iso | 2008 |
Flexible dosing of adjunctive zonisamide in the treatment of adult partial-onset seizures: a non-comparative, open-label study (ZEUS).
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anticonvulsants; Confidence Intervals; Dose-Response | 2010 |
Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Double-Blind Method; Epilepsies, Partial; Female; Humans; Isoxazoles; Male; | 2011 |
Quality of life in patients with partial-onset seizures under adjunctive therapy with zonisamide: results from a prospective non-interventional surveillance study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Doubl | 2011 |
Short-term efficacy and safety of zonisamide as adjunctive treatment for refractory partial seizures: a multicenter open-label single-arm trial in Korean patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsies, Partial; Fem | 2012 |
Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Delayed-Action Preparations; Double-Blind M | 2012 |
Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Dru | 2004 |
Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Child; Dose-Response Relationship, Drug; Doub | 2005 |
Zonisamide as adjunctive therapy for refractory partial seizures.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combinatio | 2006 |
Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Adminis | 2009 |
Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial.
Topics: Adolescent; Adult; Anticonvulsants; Double-Blind Method; Epilepsies, Partial; Europe; Female; Humans | 1993 |
Developmental and therapeutic pharmacology of antiepileptic drugs.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Admini | 2000 |
Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 2001 |
30 other studies available for zonisamide and Abdominal Epilepsy
| Article | Year |
|---|---|
Effectiveness of zonisamide in childhood refractory epilepsy.
Topics: Child; Drug Resistant Epilepsy; Epilepsies, Partial; Epilepsy; Humans; Reproducibility of Results; R | 2022 |
Efficacy, tolerability, and retention rates of zonisamide in older adult patients with focal-onset epilepsy: Experiences from two tertiary epilepsy centers.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Tolerance; Epilepsies, Partial; Female; Huma | 2017 |
Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system.
Topics: Adult; Anticonvulsants; Computer Simulation; Cost-Benefit Analysis; Disease Progression; Epilepsies, | 2019 |
Partial epilepsy and developmental delay in infant with ring chromosome 14.
Topics: Anticonvulsants; Benzodiazepines; Child, Preschool; Chromosome Disorders; Chromosomes, Human, Pair 1 | 2013 |
[Othello syndrome secondary to zonisamide].
Topics: Adult; Anticonvulsants; Brain Diseases; Cysts; Delusions; Drug Substitution; Drug Therapy, Combinati | 2014 |
[Reversible neuropsychological deterioration associated to zonisamide in a paediatric patient with tuberous sclerosis].
Topics: Acetamides; Anticonvulsants; Benzodiazepines; Child; Clobazam; Cognition Disorders; Dibenzazepines; | 2015 |
Long-term effect of antiepileptic drug switch on serum lipids and C-reactive protein.
Topics: Anticonvulsants; Biomarkers; C-Reactive Protein; Carbamazepine; Drug Substitution; Drug Therapy, Com | 2016 |
Effect of topiramate and zonisamide on fMRI cognitive networks.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Sectional Studies; Epilepsies, Partial; Fe | 2017 |
Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.
Topics: Adult; Ambulances; Anticonvulsants; Case-Control Studies; Cost Savings; Drug Costs; Drugs, Generic; | 2009 |
Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.
Topics: Adult; Ambulances; Anticonvulsants; Case-Control Studies; Cost Savings; Drug Costs; Drugs, Generic; | 2009 |
Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.
Topics: Adult; Ambulances; Anticonvulsants; Case-Control Studies; Cost Savings; Drug Costs; Drugs, Generic; | 2009 |
Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.
Topics: Adult; Ambulances; Anticonvulsants; Case-Control Studies; Cost Savings; Drug Costs; Drugs, Generic; | 2009 |
[Zonisamide as add-on treatment for focal epilepsies. An outcome analysis of 74 patients].
Topics: Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ele | 2008 |
[New antiepileptic drugs].
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsies, Partial; Epilepsy; | 2009 |
Moderate toxic effects following acute zonisamide overdose.
Topics: Adult; Anticonvulsants; Central Nervous System Diseases; Drug Overdose; Epilepsies, Partial; Female; | 2011 |
Another option for first-line treatment of partial epilepsy?
Topics: Anticonvulsants; Carbamazepine; Epilepsies, Partial; Female; Humans; Isoxazoles; Male; Zonisamide | 2012 |
Effects of zonisamide as add-on therapy on sleep-wake cycle in focal epilepsy: a polysomnographic study.
Topics: Adult; Aged; Anticonvulsants; Cerebral Cortex; Epilepsies, Partial; Female; Humans; Isoxazoles; Male | 2013 |
The 'number needed to treat' with levetiracetam (LEV): comparison with the other new antiepileptic drugs (AEDs).
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Cyclohexanecarboxylic Ac | 2002 |
Selective mutism and obsessive compulsive disorders associated with zonisamide.
Topics: Adolescent; Anticonvulsants; Epilepsies, Partial; Female; Humans; Isoxazoles; Male; Mutism; Obsessiv | 2002 |
[Effective and 15 years experience. New add-on option in epilepsy therapy]].
Topics: Anticonvulsants; Body Weight; Child; Controlled Clinical Trials as Topic; Dose-Response Relationship | 2005 |
Efficacy of levetiracetam at 12 months in children classified by seizure type, cognitive status, and previous anticonvulsant drug use.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Cognition; Dose-Response Relationship, | 2005 |
Broad-spectrum efficacy of zonisamide at 12 months in children with intractable epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Cognition; Dose-Response Relationship, | 2005 |
Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Cohort Studies; Epilepsies, Partial; Epilepsy, Generalized; Fema | 2006 |
[New medications; zonisamide].
Topics: Anticonvulsants; Calcium Channels; Epilepsies, Partial; Humans; Isoxazoles; Sodium Channels; Synapti | 2006 |
Two epileptics showing antiepileptic drug-induced psychoses.
Topics: Adolescent; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electroenc | 1993 |
Gynaecomastia in association with phenytoin and zonisamide in a patient having a CYP2C subfamily mutation.
Topics: Adult; Anticonvulsants; Epilepsies, Partial; Gynecomastia; Humans; Isoxazoles; Male; Metabolism, Inb | 1998 |
Zonisamide approved for partial seizures.
Topics: Anticonvulsants; Epilepsies, Partial; Humans; Isoxazoles; United States; United States Food and Drug | 2000 |
Renal tubular acidosis associated with zonisamide therapy.
Topics: Acidosis, Renal Tubular; Anticonvulsants; Blood Gas Analysis; Child; Electrolytes; Epilepsies, Parti | 2000 |
Contrasting effects of zonisamide and acetazolamide on amygdaloid kindling in rats.
Topics: Acetazolamide; Amygdala; Animals; Anticonvulsants; Carbonic Anhydrase Inhibitors; Disease Models, An | 2001 |
Randomized controlled trial of zonisamide for the treatment of partial-onset seizures.
Topics: Anticonvulsants; Epilepsies, Partial; Humans; Isoxazoles; Randomized Controlled Trials as Topic; Zon | 2002 |
Methodological requirements for clinical trials in refractory epilepsies--our experience with zonisamide.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Clinical Trials as Topic; Epilepsies, Partial; | 1992 |
Reversal of MRI lesion with relapse and remission of partial motor seizures in epilepsia partialis continua.
Topics: Adolescent; Anticonvulsants; Cerebral Cortex; Drug Therapy, Combination; Electroencephalography; Epi | 1991 |
The antiepileptic effect of zonisamide on patients with refractory seizures and its side effect.
Topics: Adult; Anticonvulsants; Electroencephalography; Epilepsies, Partial; Epilepsy; Epilepsy, Absence; Ep | 1988 |